NZ520141A - Benzenesulphonamide derivatives of phenyl propanoic acid useful for treating cardiovascular diseases - Google Patents
Benzenesulphonamide derivatives of phenyl propanoic acid useful for treating cardiovascular diseasesInfo
- Publication number
- NZ520141A NZ520141A NZ520141A NZ52014102A NZ520141A NZ 520141 A NZ520141 A NZ 520141A NZ 520141 A NZ520141 A NZ 520141A NZ 52014102 A NZ52014102 A NZ 52014102A NZ 520141 A NZ520141 A NZ 520141A
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- group
- optionally substituted
- phenyl
- ethyl
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title description 31
- 235000019260 propionic acid Nutrition 0.000 title description 22
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical class NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 116
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 80
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 42
- 125000005843 halogen group Chemical group 0.000 claims abstract description 29
- 239000002253 acid Substances 0.000 claims abstract description 27
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000003118 aryl group Chemical group 0.000 claims abstract description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 7
- 101150100032 Tbxa2r gene Proteins 0.000 claims abstract description 5
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 5
- 125000004385 trihaloalkyl group Chemical group 0.000 claims abstract description 5
- 125000003277 amino group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 38
- 238000002474 experimental method Methods 0.000 claims description 27
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- -1 morpholino, piperidyl Chemical group 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000746 purification Methods 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 150000002148 esters Chemical group 0.000 claims description 7
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 125000005544 phthalimido group Chemical group 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940076279 serotonin Drugs 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 claims description 3
- 108091005479 5-HT2 receptors Proteins 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 208000009079 Bronchial Spasm Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 238000006264 debenzylation reaction Methods 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 3
- 208000037997 venous disease Diseases 0.000 claims description 3
- NOKGPSRNABBBRI-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-(2-pyrrolidin-1-ylethoxy)phenyl]ethyl]phenyl]propanoic acid Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCN2CCCC2)=CC(CCC(=O)O)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 NOKGPSRNABBBRI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004623 platelet-rich plasma Anatomy 0.000 claims 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- LSGQKITYBRBEDP-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-(2-morpholin-4-ylethoxy)phenyl]ethyl]phenyl]propanoic acid Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCN2CCOCC2)=CC(CCC(=O)O)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 LSGQKITYBRBEDP-UHFFFAOYSA-N 0.000 claims 1
- OGGCYQKPNONLJU-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-[3-(dimethylamino)propoxy]phenyl]ethyl]phenyl]propanoic acid Chemical compound CN(C)CCCOC1=CC=CC=C1CCC1=CC(CCNS(=O)(=O)C=2C=CC(Cl)=CC=2)=CC(CCC(O)=O)=C1 OGGCYQKPNONLJU-UHFFFAOYSA-N 0.000 claims 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 229940102884 adrenalin Drugs 0.000 claims 1
- 230000002744 anti-aggregatory effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 229940100445 wheat starch Drugs 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 abstract description 5
- 239000002464 receptor antagonist Substances 0.000 abstract description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 75
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 64
- 239000000047 product Substances 0.000 description 63
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 28
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 238000004587 chromatography analysis Methods 0.000 description 19
- 238000004452 microanalysis Methods 0.000 description 18
- 239000000377 silicon dioxide Substances 0.000 description 17
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 11
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 7
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 7
- 239000000908 ammonium hydroxide Substances 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- FEKLXZOYEQJIBC-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]phenol Chemical compound CN(C)CCOC1=CC=C(O)C=C1 FEKLXZOYEQJIBC-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- FKKZGQXMWVGPMH-UHFFFAOYSA-N (2-hydroxyphenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].OC1=CC=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 FKKZGQXMWVGPMH-UHFFFAOYSA-N 0.000 description 2
- ZLDMZIXUGCGKMB-UHFFFAOYSA-N 3,5-dibromobenzaldehyde Chemical compound BrC1=CC(Br)=CC(C=O)=C1 ZLDMZIXUGCGKMB-UHFFFAOYSA-N 0.000 description 2
- USROQQUKEBHOFF-UHFFFAOYSA-N 3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid;hydron;chloride Chemical compound Cl.C1CC(CN)CCC1C(=O)OC1=CC=C(CCC(O)=O)C=C1 USROQQUKEBHOFF-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- ZWZUFQPXYVYAFO-UHFFFAOYSA-N Tert-butyl (triphenylphosphoranylidene)acetate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OC(C)(C)C)C1=CC=CC=C1 ZWZUFQPXYVYAFO-UHFFFAOYSA-N 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000005526 vasoconstrictor agent Substances 0.000 description 2
- MCAIDINWZOCYQK-UHFFFAOYSA-N (2-phenylmethoxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1OCC1=CC=CC=C1 MCAIDINWZOCYQK-UHFFFAOYSA-N 0.000 description 1
- ZQNSHKZQTZSNTB-UHFFFAOYSA-N (3,5-dibromophenyl)methanol Chemical compound OCC1=CC(Br)=CC(Br)=C1 ZQNSHKZQTZSNTB-UHFFFAOYSA-N 0.000 description 1
- BCGBWULHMKIMFQ-UHFFFAOYSA-M (3,5-dibromophenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].BrC1=CC(Br)=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BCGBWULHMKIMFQ-UHFFFAOYSA-M 0.000 description 1
- CELRQNUGSXYMFT-UHFFFAOYSA-N (4-hydroxyphenyl)methyl-triphenylphosphanium;bromide Chemical compound [Br-].C1=CC(O)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CELRQNUGSXYMFT-UHFFFAOYSA-N 0.000 description 1
- YWDUZLFWHVQCHY-UHFFFAOYSA-N 1,3,5-tribromobenzene Chemical compound BrC1=CC(Br)=CC(Br)=C1 YWDUZLFWHVQCHY-UHFFFAOYSA-N 0.000 description 1
- NKWSVPBDZHIPCV-UHFFFAOYSA-N 2-(2-phenylmethoxyphenyl)acetaldehyde Chemical compound O=CCC1=CC=CC=C1OCC1=CC=CC=C1 NKWSVPBDZHIPCV-UHFFFAOYSA-N 0.000 description 1
- YCNYWVSIUVKZDG-AATRIKPKSA-N 2-[(e)-2-(3,5-dibromophenyl)ethenyl]phenol Chemical compound OC1=CC=CC=C1\C=C\C1=CC(Br)=CC(Br)=C1 YCNYWVSIUVKZDG-AATRIKPKSA-N 0.000 description 1
- RZBNVKABGYIPRU-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]phenol Chemical compound CN(C)CCOC1=CC=CC=C1O RZBNVKABGYIPRU-UHFFFAOYSA-N 0.000 description 1
- RBUHQVVKEDDPLO-UHFFFAOYSA-N 2-[3-(dimethylamino)propoxy]phenol Chemical compound CN(C)CCCOC1=CC=CC=C1O RBUHQVVKEDDPLO-UHFFFAOYSA-N 0.000 description 1
- HEKGBZSGYHVJLI-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-[2-(dimethylamino)ethoxy]phenyl]ethyl]phenyl]propanoic acid Chemical compound CN(C)CCOC1=CC=CC=C1CCC1=CC(CCNS(=O)(=O)C=2C=CC(Cl)=CC=2)=CC(CCC(O)=O)=C1 HEKGBZSGYHVJLI-UHFFFAOYSA-N 0.000 description 1
- CAJUAYJQXHOQRZ-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethoxy]phenyl]ethyl]phenyl]propanoic acid Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCN2CCC(CC2)C=2C3=CC=C(F)C=C3ON=2)=CC(CCC(=O)O)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 CAJUAYJQXHOQRZ-UHFFFAOYSA-N 0.000 description 1
- MTQLSGYXCNZOGI-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-[4-(dimethylamino)butoxy]phenyl]ethyl]phenyl]propanoic acid Chemical compound CN(C)CCCCOC1=CC=CC=C1CCC1=CC(CCNS(=O)(=O)C=2C=CC(Cl)=CC=2)=CC(CCC(O)=O)=C1 MTQLSGYXCNZOGI-UHFFFAOYSA-N 0.000 description 1
- TZPRHLMEZOXHOB-UHFFFAOYSA-N 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[[2-[3-(dimethylamino)propoxy]phenyl]methyl]phenyl]propanoic acid;hydrochloride Chemical compound Cl.CN(C)CCCOC1=CC=CC=C1CC1=CC(CCNS(=O)(=O)C=2C=CC(Cl)=CC=2)=CC(CCC(O)=O)=C1 TZPRHLMEZOXHOB-UHFFFAOYSA-N 0.000 description 1
- OBIVJICFQBTBTE-UHFFFAOYSA-N 3-[4-(3-chloropropyl)piperazin-1-yl]-1,2-benzothiazole Chemical compound C1CN(CCCCl)CCN1C1=NSC2=CC=CC=C12 OBIVJICFQBTBTE-UHFFFAOYSA-N 0.000 description 1
- DXLSPULVTHNVPX-UHFFFAOYSA-N 3-bromo-5-(hydroxymethyl)benzaldehyde Chemical compound OCC1=CC(Br)=CC(C=O)=C1 DXLSPULVTHNVPX-UHFFFAOYSA-N 0.000 description 1
- KYTJKJFAPVIDMV-AATRIKPKSA-N 3-bromo-5-[(e)-2-(2-hydroxyphenyl)ethenyl]benzaldehyde Chemical compound OC1=CC=CC=C1\C=C\C1=CC(Br)=CC(C=O)=C1 KYTJKJFAPVIDMV-AATRIKPKSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- XJFFUXNWVUZUIF-UHFFFAOYSA-N 4-ethenylisoindole-1,3-dione Chemical compound C=CC1=CC=CC2=C1C(=O)NC2=O XJFFUXNWVUZUIF-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- KVYDNRLPXDVCKT-UHFFFAOYSA-N C(C)(C)(C)OC(CCC1=CC(=CC(=C1)CCNS(=O)(=O)C1=CC=C(C=C1)Cl)CCC1=C(C=CC=C1)OCCN1CCN(CC1)C1=NSC2=C1C=CC=C2)=O Chemical compound C(C)(C)(C)OC(CCC1=CC(=CC(=C1)CCNS(=O)(=O)C1=CC=C(C=C1)Cl)CCC1=C(C=CC=C1)OCCN1CCN(CC1)C1=NSC2=C1C=CC=C2)=O KVYDNRLPXDVCKT-UHFFFAOYSA-N 0.000 description 1
- KLOWDUKFCQDVAU-SNAWJCMRSA-N CC(C)(C)OC(=O)\C=C\C1=CC(Br)=CC(CO)=C1 Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC(Br)=CC(CO)=C1 KLOWDUKFCQDVAU-SNAWJCMRSA-N 0.000 description 1
- DYQQPXRWCUWEHT-WNBKNDGGSA-N CC(C)(C)OC(=O)\C=C\C1=CC(Br)=CC(C\C=C\C=2C(=CC=CC=2)OCC=2C=CC=CC=2)=C1 Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC(Br)=CC(C\C=C\C=2C(=CC=CC=2)OCC=2C=CC=CC=2)=C1 DYQQPXRWCUWEHT-WNBKNDGGSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940099508 TP receptor antagonist Drugs 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000000328 pro-aggregatory effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- CXIABERBBQLZFZ-UHFFFAOYSA-N tert-butyl 3-[3-(2-aminoethyl)-5-[2-[2-(2-morpholin-4-ylethoxy)phenyl]ethyl]phenyl]propanoate Chemical compound CC(C)(C)OC(=O)CCC1=CC(CCN)=CC(CCC=2C(=CC=CC=2)OCCN2CCOCC2)=C1 CXIABERBBQLZFZ-UHFFFAOYSA-N 0.000 description 1
- IYSSAASQVUDUCP-UHFFFAOYSA-N tert-butyl 3-[3-(2-aminoethyl)-5-[2-[2-(2-pyrrolidin-1-ylethoxy)phenyl]ethyl]phenyl]propanoate Chemical compound CC(C)(C)OC(=O)CCC1=CC(CCN)=CC(CCC=2C(=CC=CC=2)OCCN2CCCC2)=C1 IYSSAASQVUDUCP-UHFFFAOYSA-N 0.000 description 1
- BPCJHHJDAAEOBB-UHFFFAOYSA-N tert-butyl 3-[3-(2-aminoethyl)-5-[2-[2-[2-(dimethylamino)ethoxy]phenyl]ethyl]phenyl]propanoate Chemical compound CN(C)CCOC1=CC=CC=C1CCC1=CC(CCN)=CC(CCC(=O)OC(C)(C)C)=C1 BPCJHHJDAAEOBB-UHFFFAOYSA-N 0.000 description 1
- NWMKFWORTAGRLM-UHFFFAOYSA-N tert-butyl 3-[3-(2-aminoethyl)-5-[2-[2-[3-(dimethylamino)propoxy]phenyl]ethyl]phenyl]propanoate Chemical compound CN(C)CCCOC1=CC=CC=C1CCC1=CC(CCN)=CC(CCC(=O)OC(C)(C)C)=C1 NWMKFWORTAGRLM-UHFFFAOYSA-N 0.000 description 1
- NGWOQLQODDUAQV-UHFFFAOYSA-N tert-butyl 3-[3-(2-aminoethyl)-5-[2-[4-[2-(dimethylamino)ethoxy]phenyl]ethyl]phenyl]propanoate Chemical compound C1=CC(OCCN(C)C)=CC=C1CCC1=CC(CCN)=CC(CCC(=O)OC(C)(C)C)=C1 NGWOQLQODDUAQV-UHFFFAOYSA-N 0.000 description 1
- IUUAENIIBRTNOA-UHFFFAOYSA-N tert-butyl 3-[3-[2-(benzenesulfonamido)ethyl]-5-[2-[2-[3-(dimethylamino)propoxy]phenyl]ethyl]phenyl]propanoate Chemical compound CN(C)CCCOC1=CC=CC=C1CCC1=CC(CCNS(=O)(=O)C=2C=CC=CC=2)=CC(CCC(=O)OC(C)(C)C)=C1 IUUAENIIBRTNOA-UHFFFAOYSA-N 0.000 description 1
- XNLVQCKHDZSMQW-UHFFFAOYSA-N tert-butyl 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-(2-morpholin-4-ylethoxy)phenyl]ethyl]phenyl]propanoate Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCN2CCOCC2)=CC(CCC(=O)OC(C)(C)C)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 XNLVQCKHDZSMQW-UHFFFAOYSA-N 0.000 description 1
- HYHGVLAFFWRJDD-UHFFFAOYSA-N tert-butyl 3-[3-[2-[(4-chlorophenyl)sulfonylamino]ethyl]-5-[2-[2-(2-pyrrolidin-1-ylethoxy)phenyl]ethyl]phenyl]propanoate Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCN2CCCC2)=CC(CCC(=O)OC(C)(C)C)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 HYHGVLAFFWRJDD-UHFFFAOYSA-N 0.000 description 1
- LMQMVUGXOAXDHV-UHFFFAOYSA-N tert-butyl 3-[3-[2-[2-[3-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]propoxy]phenyl]ethyl]-5-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]propanoate Chemical compound C=1C(CCC=2C(=CC=CC=2)OCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)=CC(CCC(=O)OC(C)(C)C)=CC=1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 LMQMVUGXOAXDHV-UHFFFAOYSA-N 0.000 description 1
- DUKCNMAUCHJLEG-UHFFFAOYSA-N tert-butyl 3-[3-[2-[4-[2-(dimethylamino)ethoxy]phenyl]ethyl]-5-[2-(1,3-dioxoisoindol-2-yl)ethyl]phenyl]propanoate Chemical compound C1=CC(OCCN(C)C)=CC=C1CCC1=CC(CCN2C(C3=CC=CC=C3C2=O)=O)=CC(CCC(=O)OC(C)(C)C)=C1 DUKCNMAUCHJLEG-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0109339A FR2827280B1 (fr) | 2001-07-13 | 2001-07-13 | Nouveaux derives de benzene sulfonamide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ520141A true NZ520141A (en) | 2003-11-28 |
Family
ID=8865462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ520141A NZ520141A (en) | 2001-07-13 | 2002-07-12 | Benzenesulphonamide derivatives of phenyl propanoic acid useful for treating cardiovascular diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6541471B1 (enExample) |
| EP (1) | EP1275641B1 (enExample) |
| JP (1) | JP3770858B2 (enExample) |
| KR (1) | KR100503157B1 (enExample) |
| CN (1) | CN1186318C (enExample) |
| AR (1) | AR035257A1 (enExample) |
| AT (1) | ATE286877T1 (enExample) |
| AU (1) | AU2002300092B2 (enExample) |
| BR (1) | BR0202685A (enExample) |
| CA (1) | CA2393995C (enExample) |
| DE (1) | DE60202554T2 (enExample) |
| DK (1) | DK1275641T3 (enExample) |
| EA (1) | EA005376B1 (enExample) |
| ES (1) | ES2234994T3 (enExample) |
| FR (1) | FR2827280B1 (enExample) |
| HU (1) | HUP0202284A3 (enExample) |
| MX (1) | MXPA02006853A (enExample) |
| NO (1) | NO20023390L (enExample) |
| NZ (1) | NZ520141A (enExample) |
| PL (1) | PL355009A1 (enExample) |
| PT (1) | PT1275641E (enExample) |
| SI (1) | SI1275641T1 (enExample) |
| ZA (1) | ZA200205597B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106083546A (zh) * | 2016-06-20 | 2016-11-09 | 上海引盛生物科技有限公司 | 一种3,5‑二溴苯甲醛的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02304022A (ja) * | 1989-05-18 | 1990-12-17 | Mitsubishi Kasei Corp | セロトニン拮抗剤 |
| US5364866A (en) * | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
| ATE167473T1 (de) * | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| TW219358B (enExample) * | 1991-12-20 | 1994-01-21 | Hokuriku Pharmaceutical | |
| GB9220137D0 (en) * | 1992-09-23 | 1992-11-04 | Pfizer Ltd | Therapeutic agents |
| JPH0753505A (ja) * | 1992-10-01 | 1995-02-28 | Hokuriku Seiyaku Co Ltd | ベンゼンスルホンアミド誘導体及びその用途 |
| FR2760235B1 (fr) * | 1997-02-28 | 1999-04-09 | Adir | Nouveaux derives de benzenesulfonylamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2001
- 2001-07-13 FR FR0109339A patent/FR2827280B1/fr not_active Expired - Fee Related
-
2002
- 2002-07-11 MX MXPA02006853A patent/MXPA02006853A/es active IP Right Grant
- 2002-07-11 ES ES02291747T patent/ES2234994T3/es not_active Expired - Lifetime
- 2002-07-11 SI SI200230073T patent/SI1275641T1/xx unknown
- 2002-07-11 DE DE60202554T patent/DE60202554T2/de not_active Expired - Fee Related
- 2002-07-11 DK DK02291747T patent/DK1275641T3/da active
- 2002-07-11 PL PL02355009A patent/PL355009A1/xx not_active Application Discontinuation
- 2002-07-11 AT AT02291747T patent/ATE286877T1/de not_active IP Right Cessation
- 2002-07-11 EP EP02291747A patent/EP1275641B1/fr not_active Expired - Lifetime
- 2002-07-11 PT PT02291747T patent/PT1275641E/pt unknown
- 2002-07-12 AR ARP020102609A patent/AR035257A1/es not_active Application Discontinuation
- 2002-07-12 ZA ZA200205597A patent/ZA200205597B/xx unknown
- 2002-07-12 BR BR0202685-6A patent/BR0202685A/pt not_active IP Right Cessation
- 2002-07-12 NZ NZ520141A patent/NZ520141A/en unknown
- 2002-07-12 EA EA200200666A patent/EA005376B1/ru not_active IP Right Cessation
- 2002-07-12 JP JP2002203408A patent/JP3770858B2/ja not_active Expired - Fee Related
- 2002-07-12 NO NO20023390A patent/NO20023390L/no not_active Application Discontinuation
- 2002-07-12 AU AU2002300092A patent/AU2002300092B2/en not_active Ceased
- 2002-07-12 US US10/195,018 patent/US6541471B1/en not_active Expired - Fee Related
- 2002-07-12 HU HU0202284A patent/HUP0202284A3/hu unknown
- 2002-07-13 KR KR10-2002-0040946A patent/KR100503157B1/ko not_active Expired - Fee Related
- 2002-07-15 CN CNB021241627A patent/CN1186318C/zh not_active Expired - Fee Related
- 2002-07-15 CA CA002393995A patent/CA2393995C/fr not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040242589A1 (en) | 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
| JP2000504677A (ja) | ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
| EA006430B1 (ru) | Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции | |
| JP4390698B2 (ja) | Ｃｎｓ障害の処置のための５−ｈｔ６レセプターモジュレーターとしての１−スルホニル−４−アミノアルコキシインドール誘導体 | |
| EP0925303A1 (en) | Phosphinic acid amides as matrix metalloprotease inhibitors | |
| FR2735127A1 (fr) | Nouvelles piperazines heteroaromatiques utiles comme medicaments. | |
| FR2669336A1 (fr) | Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EP0773937A1 (fr) | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant | |
| CA2264266A1 (en) | 1,3-diheterocyclic metalloprotease inhibitors | |
| EP2651416A1 (en) | Compounds useful for treating aids | |
| WO2004080986A1 (en) | Phenyl sulfone derivatives and their use in the treatment of cns disorders | |
| EP0553016B1 (fr) | Nouveaux amides et sulfonamides naphtaleniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| US6469011B2 (en) | Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists | |
| EP2062881B1 (en) | Process for making N-(diphenylmethyl)piperazines | |
| TWI552985B (zh) | N-hydroxymethylamine derivatives and pharmaceuticals containing them | |
| AU2002300093B2 (en) | New benzenesulphonamide compounds, a process for their preparation and pharmaceutical compositions containing them | |
| NZ520141A (en) | Benzenesulphonamide derivatives of phenyl propanoic acid useful for treating cardiovascular diseases | |
| US5071858A (en) | Antipsychotic benzothiopyranylamines | |
| JP4162991B2 (ja) | Ｎｍｄａ受容体リガンドに対するプロドラッグ | |
| SU810080A3 (ru) | Способ получени производных дибензо/ / /1,3,6/ диОКСАзОциНАили иХ КиСлОТНО-АддиТиВНыХ СОлЕй | |
| CN100378086C (zh) | 哌嗪衍生物和它们作为合成中间体的应用 | |
| JP4454314B2 (ja) | ４−（ジアリールメチル）−１−ピペラジニル誘導体 | |
| JPH0551588B2 (enExample) | ||
| WO2006080284A1 (ja) | ２－置換イミノ－１，３－オキサジン誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |